摘要
目的 探讨吡嗪酰胺、帕司烟肼在初治涂阳肺结核患者治疗中的预后效果。方法 60例初治涂阳肺结核患者,随机分为对照组及研究组,每组30例。对照组采用帕司烟肼治疗,研究组采用吡嗪酰胺治疗。比较两组患者痰转阴率、病灶改善情况及不良反应发生率。结果 治疗3、6个月后,研究组的痰转阴率分别为90.0%、96.7%,高于对照组的66.7%、80.0%,差异具有统计学意义(P<0.05)。研究组的病灶改善总有效率93.3%明显高于对照组的73.3%,差异具有统计学意义(P<0.05)。研究组不良反应发生率6.7%低于对照组的26.7%,差异具有统计学意义(P<0.05)。结论 吡嗪酰胺与帕司烟肼相比,对初治涂阳肺结核患者的治疗有效率高,且患者的不良反应发生率较低。
Objective To discuss the prognostic effect of pyrazinamide and pasiniazid in the treatment of newly diagnosed smear-positive pulmonary tuberculosis patients.Methods A total of 60 patients with newly diagnosed smear-positive tuberculosis were randomly divided into control group and research group,with 30 cases in each group.The control group was treated with pasiniazid,and the research group was treated with pyrazinamide.The sputum negative conversion rate,improvement of focus and incidence of adverse reactions were compared between the two groups.Results After 3 and 6 months of treatment,the sputum negative conversion rates in the research group were 90.0%and 96.7%,which were higher than 66.7%and 80.0%in the control group,and the differences were all statistically significant(P<0.05).The total effective rate of focus improvement in the research group was 93.3%,which was significantly higher than 73.3%in the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions 6.7%in the research group was lower than 26.7%in the control group,and the difference was statistically significant(P<0.05).Conclusion Compared with pasiniazid,pyrazinamide is more effective in the treatment of newly diagnosed smear-positive pulmonary tuberculosis patients,and the incidence of adverse reactions in patients is lower.
作者
林晓丽
LIN Xiao-li(Jieyang Chronic Disease Control Center,Jieyang 522000,China)
出处
《中国现代药物应用》
2022年第19期123-125,共3页
Chinese Journal of Modern Drug Application
关键词
吡嗪酰胺
帕司烟肼
肺结核
痰转阴率
Pyrazinamide
Pasiniazid
Pulmonary tuberculosis
Sputum negative conversion rate
